SER
MaterialsAgeX Therapeutics Inc
$1.83+0.03 (+1.67%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving SER Today?
No stock-specific AI insight has been generated for SER yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$27M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume44K
Avg Volume (10D)—
Shares Outstanding14.9M
SER News
20 articles- Serina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitGlobeNewswire Inc.·Apr 7, 2026
- Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanYahoo Finance·Apr 2, 2026
- Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 25, 2026
- Serina Therapeutics to Present at the 38th Annual Roth ConferenceYahoo Finance·Mar 24, 2026
- Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseYahoo Finance·Mar 18, 2026
- Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseYahoo Finance·Feb 24, 2026
- Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's DiseaseYahoo Finance·Feb 19, 2026
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar EventYahoo Finance·Feb 3, 2026
- Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s diseaseYahoo Finance·Jan 28, 2026
- Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' EquityYahoo Finance·Jan 15, 2026
- Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of ChemistryYahoo Finance·Dec 11, 2025
- Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 ProgramYahoo Finance·Dec 10, 2025
- Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsYahoo Finance·Nov 13, 2025
- Serina Therapeutics Provides Regulatory Update on SER-252 ProgramYahoo Finance·Nov 3, 2025
- Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and InvestorsYahoo Finance·Oct 8, 2025
- Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s DiseaseYahoo Finance·Oct 6, 2025
- Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s DiseaseYahoo Finance·Sep 9, 2025
- Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 8, 2025
- Fed Politics Weigh on Investor Sentiment, Driving Muted Premarket Action for US Equity FuturesYahoo Finance·Aug 26, 2025
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Economic Data, Trump Orders to Remove Lisa CookYahoo Finance·Aug 26, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.80
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$27M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume44K
Avg Volume (10D)—
Shares Outstanding14.9M
About AgeX Therapeutics Inc
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeAMEX
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—